SynthesisFrontiers in oncology2020

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.

Abdulaali R Almutairi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.